Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis

Abstract

In recent years, CD133 has been identified as a cancer stem cell (CSC) marker in gliomas. Nevertheless, the clinical and prognostic value of CD133 in glioma patients remains controversial. Therefore, we conducted a systematic meta-analysis to evaluate the correlation of CD133 with World Health Organization (WHO) grade, age, gender, overall survival (OS), and progression-free survival (PFS) in glioma patients. Eligible studies on this subject were included, and then pooled odd ratios (ORs) and hazard ratios (HRs) with 95 % confidence intervals (95 % CIs) were estimated. Publication bias was assessed by the funnel plots, and heterogeneity and sensitivity were analyzed as well. In the present study, 21 articles with the total number of 1535 patients were included. High expression of CD133 in glioma patients was associated with high WHO grade (III + IV) (n = 11, OR 5.10, 95 % CI 2.99-8.69; p = 0.000), rather than age (n = 4, OR 2.54, 95 % CI 0.68-9.52; p = 0.167) and gender (n = 4, OR 0.71, 95 % CI 0.21-2.45; p = 0.587). In addition, survival analysis demonstrated a significant association between CD133 high expression and poor 2-year OS (n = 11, HR 2.18, 95 % CI 1.29-3.7; p = 0.004), 5-year OS (n = 4, HR 10.39, 95 % CI 2.59-41.63; p = 0.001), as well as PFS (n = 10, HR 2.34, 95 % CI 1.62-3.37; p = 0.000). Taken together, this study suggests that CD133 expression correlates to higher grade of gliomas and worse prognosis in glioma patients. Thus, CD133 could be recommended as a useful pathological and prognostic biomarker in clinical practice.

Combination therapy with micellarized cyclopamine and temozolomide attenuate glioblastoma growth through Gli1 down-regulation

“…The Shh pathway has a positive correlation with CD133 + expression in glioma CSC [40]. From a clinical perspective, CD133 is a significant indicator for patients with poor prognosis and high glioma grade [41]. Cyp was proposed to inhibit the stem cell-like behavior through Shh inhibition and therefore attenuate the CD133 + expression.…”

CD133 in brain tumor: the prognostic factor

“…Almost a decade ago, a correlation between CD133-positivity in glioma specimens and poor patient prognosis was reported [16], and its prognostic significance in glioma has since been demonstrated in two independent meta-analyses [17, 18]. Molecular mechanisms of CD133-mediated glioma progression have been further revealed recently.…”

Molecular markers of cancer stem cells verified in vivo

“…Так, в четырёх работах, посвященных изучению немелкоклеточного рака лёгких, исследователи приводят данные о корреляции между экспрессией CD133 с более низкой общей выживаемостью [11,32,33], наличием метастазов в лимфатические узлы [11,33,34], а также с более низкой степенью дифференцировки клеток опухоли [11,32,34]. Результаты трёх подобных мета-анализов в отношении злокачественной глиомы также показывают статистически значимую корреляцию между экспрессией CD133 и более низкими общей выживаемостью [35][36][37] и выживаемостью без прогрессирования заболевания [35,37], а также третьей и четвёртой стадиями прогрессии глиомы [36]. Проведено два подобных исследования в отношении колоректальной карциномы [38,39] и два для карциномы желудка [40,41], в которых также демонстрируется корреляция между повышенной экспрессией проминина-1 и низкой общей выживаемостью.…”